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Objectives: To investigate the mechanisms underlying the effects of interferon-gamma on 
macrophages in atherosclerosis and how therapeutic agents attenuate the actions of this 
pro-inflammatory cytokine. 
Background: Atherosclerosis is an inflammatory disease of medium and large arteries 
regulated by cytokines. The pro-atherogenic cytokine interferon-gamma (IFN-gamma) 
plays a pivotal role in all stages of the disease and hence represents a promising 
therapeutic target. The purpose of this study was to investigate how IFN-gamma 
modulates macrophage function and properties in this disease along with the mechanisms 
underlying the inhibition of its actions by therapeutic agents. 
Methods: The studies used a combination of macrophage cell lines and primary cultures 
together with analysis of gene expression and signal transduction pathways, RNA 
interference assays and biochemical approaches. 
Results: IFN-gamma induced macrophage foam cell formation and the expression of 
several pro-inflammatory genes, such as monocyte chemotactic protein-1 and 
intercellular adhesion molecule-1, and microRNAs. The extracellular signal-regulated 
kinase (ERK) pathway played a pivotal role in the action of the cytokine on the 
promotion of modified lipoprotein uptake by macrophages and the regulation of 
expression of pro-atherogenic genes. ERK modulated the phosphorylation-mediated 
activation of signal transducer and activator of transcription-1 (STAT1), a key 
transcription factor in IFN-gamma signalling. The pro-atherogenic actions of IFN-gamma 
were attenuated by statins, activators of anti-atherogenic nuclear receptors, and 
nutraceuticals such as dihomo-gamma-linolenic acid. The mechanisms underlying the 
inhibitory actions of such agents along with the role of the ERK:STAT1 axis in the 
promotion of atherosclerotic in vivo are currently being investigated. 
Conclusions: The studies provide key mechanistic insights into the pro-atherogenic 
actions of IFN-gamma and the effects of therapeutic agents on signalling by this 
cytokine. 
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